(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 November 2022 (17.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/238737 A1

(51) International Patent Classification:
A61K 47/55 (2017.01) *C07D 417/14* (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:
PCT/IB2021/054167

(22) International Filing Date:
14 May 2021 (14.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant: **APRINOIA THERAPEUTICS LIMITED** [CN/CN]; 31/F, Chinachem Century Tower, 178 Gloucester Road, Wanchai, Hong Kong (CN).

(72) Inventors: **JANG, Ming-Kuei**; 17F, No. 3, Park St., Nangang District, Taipei City, 11503 (TW). **TEMPEST, Paul**; No. 199, Heping East Rd., Section 3, Apt. 9-2, Xinyi District, Taipei (TW). **LIN, Yih-Shyan**; No. 232, Wenlong E. Rd., Fengshan Dist., Kaohsiung City, 830 (TW).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2022/238737 A1

(54) Title: COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF

(57) Abstract: The present disclosure provides compounds comprising an E3 ubiquitin ligase binding moiety and an alpha-synuclein protein binding moiety for use in the treatment of neurodegenerative diseases, in particular synucleinopathies.